Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly ...

A groundbreaking telehealth trial offers remote access to innovative pancreatic cancer treatment, enhancing patient ...

Sophia Kamran, MD, discussed the updated AUA guidelines on salvage therapy for patients with prostate cancer and their ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

An expert discusses how treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) increasingly depend on prior androgen receptor pathway inhibitor (ARPI) exposure, highlighting ...

A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed ...